NextCure, Inc.

NASDAQ:NXTC

1.51 (USD) • At close April 17, 2024
Bedrijfsnaam NextCure, Inc.
Symbool NXTC
Munteenheid USD
Prijs 1.51
Beurswaarde 42,133,530
Dividendpercentage 0%
52-weken bereik 0.98 - 2.57
Industrie Biotechnology
Sector Healthcare
CEO Mr. Michael S. Richman MSBA
Website https://www.nextcure.com

An error occurred while fetching data.

Over NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is

Vergelijkbare Aandelen

Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc.

TSHA

2.45 USD

KORU Medical Systems, Inc. logo

KORU Medical Systems, Inc.

KRMD

2.12 USD

Forian Inc. logo

Forian Inc.

FORA

2.66 USD

Leap Therapeutics, Inc. logo

Leap Therapeutics, Inc.

LPTX

3 USD

Immuneering Corporation logo

Immuneering Corporation

IMRX

1.86 USD

Precision BioSciences, Inc. logo

Precision BioSciences, Inc.

DTIL

11.51 USD

Champions Oncology, Inc. logo

Champions Oncology, Inc.

CSBR

5.03 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)